Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 16 | 2022 | 3354 | 1.130 |
Why?
|
| Clinical Nursing Research | 2 | 2012 | 16 | 0.820 |
Why?
|
| Taurine | 2 | 2019 | 98 | 0.810 |
Why?
|
| Hypoglycemic Agents | 12 | 2022 | 2734 | 0.810 |
Why?
|
| Research Personnel | 2 | 2017 | 513 | 0.770 |
Why?
|
| Diabetes Mellitus, Type 2 | 18 | 2022 | 10857 | 0.750 |
Why?
|
| Ethics, Nursing | 1 | 2017 | 25 | 0.650 |
Why?
|
| Codon, Terminator | 1 | 2017 | 131 | 0.630 |
Why?
|
| Blood Glucose | 15 | 2022 | 6255 | 0.490 |
Why?
|
| Legal Guardians | 1 | 2012 | 54 | 0.470 |
Why?
|
| Third-Party Consent | 1 | 2012 | 60 | 0.470 |
Why?
|
| Diabetic Angiopathies | 2 | 2014 | 846 | 0.430 |
Why?
|
| Community-Based Participatory Research | 1 | 2012 | 200 | 0.410 |
Why?
|
| Diabetes Complications | 5 | 2022 | 1394 | 0.390 |
Why?
|
| Joint Diseases | 1 | 2014 | 452 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 9488 | 0.380 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 2164 | 0.380 |
Why?
|
| Professional Role | 1 | 2012 | 299 | 0.370 |
Why?
|
| Metformin | 5 | 2022 | 800 | 0.350 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 1513 | 0.350 |
Why?
|
| Musculoskeletal Diseases | 1 | 2014 | 545 | 0.340 |
Why?
|
| Models, Nursing | 1 | 2007 | 48 | 0.330 |
Why?
|
| Insulin | 9 | 2019 | 6648 | 0.330 |
Why?
|
| Nursing Research | 1 | 2007 | 71 | 0.320 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 685 | 0.310 |
Why?
|
| Zebrafish | 1 | 2017 | 3038 | 0.280 |
Why?
|
| Gender Identity | 1 | 2010 | 554 | 0.280 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 335 | 0.260 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2022 | 378 | 0.260 |
Why?
|
| Hyperglycemia | 3 | 2022 | 1343 | 0.220 |
Why?
|
| Self Care | 3 | 2019 | 799 | 0.220 |
Why?
|
| Benchmarking | 1 | 2007 | 915 | 0.210 |
Why?
|
| Glucose | 1 | 2012 | 4261 | 0.200 |
Why?
|
| Bass | 1 | 2019 | 6 | 0.190 |
Why?
|
| Hospitals, General | 4 | 2012 | 712 | 0.190 |
Why?
|
| Intensive Care Units | 1 | 2012 | 3418 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2008 | 2102 | 0.170 |
Why?
|
| Cysteic Acid | 1 | 2017 | 2 | 0.170 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 14075 | 0.160 |
Why?
|
| Carboxy-Lyases | 1 | 2017 | 94 | 0.160 |
Why?
|
| Pamphlets | 1 | 2017 | 74 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2012 | 3266 | 0.150 |
Why?
|
| Vision, Ocular | 1 | 2019 | 466 | 0.140 |
Why?
|
| Diabetes Mellitus | 3 | 2012 | 5348 | 0.140 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 100 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 3690 | 0.140 |
Why?
|
| Hearing Loss | 2 | 2019 | 711 | 0.140 |
Why?
|
| Coronary Disease | 1 | 2010 | 6127 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2017 | 350 | 0.130 |
Why?
|
| Sulfonylurea Compounds | 3 | 2022 | 189 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 2996 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3866 | 0.130 |
Why?
|
| Gastroparesis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2022 | 1156 | 0.120 |
Why?
|
| Gastric Emptying | 1 | 2015 | 229 | 0.120 |
Why?
|
| Hashimoto Disease | 1 | 2014 | 93 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2017 | 3934 | 0.110 |
Why?
|
| Erectile Dysfunction | 1 | 2015 | 447 | 0.110 |
Why?
|
| Point Mutation | 1 | 2017 | 1656 | 0.110 |
Why?
|
| Boston | 2 | 2017 | 9402 | 0.110 |
Why?
|
| Amino Acids | 1 | 2017 | 1752 | 0.100 |
Why?
|
| Humans | 38 | 2022 | 708843 | 0.100 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 217 | 0.100 |
Why?
|
| Inpatients | 2 | 2012 | 2207 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 3 | 2022 | 672 | 0.100 |
Why?
|
| Massachusetts | 4 | 2012 | 8712 | 0.100 |
Why?
|
| Career Mobility | 1 | 2012 | 263 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2017 | 2571 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2014 | 468 | 0.090 |
Why?
|
| Automation | 1 | 2012 | 589 | 0.090 |
Why?
|
| Middle Aged | 19 | 2021 | 213752 | 0.090 |
Why?
|
| Needs Assessment | 2 | 2013 | 1147 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 2340 | 0.090 |
Why?
|
| Patient Compliance | 3 | 2019 | 2758 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2017 | 2506 | 0.090 |
Why?
|
| Nursing Evaluation Research | 1 | 2007 | 29 | 0.090 |
Why?
|
| Adult | 17 | 2022 | 211041 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39038 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 66 | 0.080 |
Why?
|
| Diabetic Retinopathy | 2 | 2015 | 1202 | 0.080 |
Why?
|
| Job Satisfaction | 1 | 2012 | 555 | 0.080 |
Why?
|
| Male | 25 | 2022 | 349524 | 0.080 |
Why?
|
| Lipids | 3 | 2021 | 3246 | 0.080 |
Why?
|
| Education, Nursing, Continuing | 1 | 2007 | 79 | 0.080 |
Why?
|
| Risk Factors | 9 | 2022 | 69553 | 0.080 |
Why?
|
| Female | 26 | 2022 | 375205 | 0.080 |
Why?
|
| Cohort Studies | 6 | 2022 | 39292 | 0.080 |
Why?
|
| Blood Pressure | 5 | 2021 | 8528 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 6562 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2014 | 1829 | 0.070 |
Why?
|
| Health Education | 1 | 2013 | 1062 | 0.070 |
Why?
|
| African Americans | 2 | 2019 | 5118 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2012 | 1470 | 0.070 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2022 | 233 | 0.070 |
Why?
|
| Menopause | 1 | 2013 | 1518 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 1047 | 0.070 |
Why?
|
| Hypertension | 2 | 2022 | 8161 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 14712 | 0.070 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 13536 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 23020 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 14215 | 0.070 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 1167 | 0.060 |
Why?
|
| Research Design | 1 | 2019 | 5833 | 0.060 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 2351 | 0.060 |
Why?
|
| Leadership | 1 | 2012 | 1325 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 712 | 0.060 |
Why?
|
| Safety Management | 1 | 2007 | 781 | 0.050 |
Why?
|
| Aged | 8 | 2021 | 161488 | 0.050 |
Why?
|
| Employment | 1 | 2008 | 1087 | 0.050 |
Why?
|
| Self Report | 1 | 2012 | 3397 | 0.050 |
Why?
|
| Young Adult | 6 | 2022 | 55940 | 0.050 |
Why?
|
| Dyslipidemias | 2 | 2022 | 843 | 0.050 |
Why?
|
| Triglycerides | 1 | 1988 | 2564 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 2046 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2012 | 2980 | 0.050 |
Why?
|
| Depressive Disorder | 2 | 2015 | 3811 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 10566 | 0.050 |
Why?
|
| Fisheries | 1 | 2019 | 27 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 8024 | 0.050 |
Why?
|
| Animal Feed | 1 | 2019 | 112 | 0.050 |
Why?
|
| Patient Selection | 1 | 2012 | 4306 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 412 | 0.040 |
Why?
|
| Disease Management | 1 | 2010 | 2536 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6530 | 0.040 |
Why?
|
| Cognition | 2 | 2021 | 5982 | 0.040 |
Why?
|
| Albuminuria | 1 | 2022 | 675 | 0.040 |
Why?
|
| Microvessels | 1 | 2022 | 565 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3885 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 58184 | 0.040 |
Why?
|
| Quality of Life | 2 | 2015 | 11594 | 0.040 |
Why?
|
| Adolescent | 8 | 2019 | 84718 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1996 | 163 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 1817 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 41038 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 2090 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2015 | 252 | 0.030 |
Why?
|
| Insulin Infusion Systems | 1 | 2015 | 217 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2014 | 100 | 0.030 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 62 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 629 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 1539 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1110 | 0.030 |
Why?
|
| Age of Onset | 1 | 2019 | 3330 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2015 | 457 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 311 | 0.030 |
Why?
|
| Algorithms | 1 | 2012 | 13647 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 697 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7487 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5235 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 1468 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 1996 | 805 | 0.020 |
Why?
|
| Microcirculation | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Perception | 1 | 2015 | 1172 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 2399 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 170486 | 0.020 |
Why?
|
| Body Weight | 1 | 2019 | 4680 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Retina | 1 | 2019 | 2649 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 1988 | 500 | 0.020 |
Why?
|
| Child | 4 | 2019 | 73636 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 910 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2455 | 0.020 |
Why?
|
| Professional-Patient Relations | 1 | 2012 | 725 | 0.020 |
Why?
|
| Pyrazines | 1 | 2013 | 1259 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 696 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 936 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2013 | 12366 | 0.020 |
Why?
|
| United States | 3 | 2018 | 67165 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2022 | 61932 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 5045 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12292 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 2119 | 0.010 |
Why?
|
| Health Status | 1 | 2015 | 4015 | 0.010 |
Why?
|
| Weight Gain | 1 | 2012 | 2193 | 0.010 |
Why?
|
| Reaction Time | 1 | 1988 | 2134 | 0.010 |
Why?
|
| Risk | 1 | 2014 | 9641 | 0.010 |
Why?
|
| Weight Loss | 1 | 2012 | 2450 | 0.010 |
Why?
|
| Cholesterol | 1 | 1988 | 2866 | 0.010 |
Why?
|
| Heart Failure | 1 | 2022 | 10040 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12447 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21194 | 0.010 |
Why?
|
| Exercise | 1 | 2013 | 5251 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 401 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1996 | 446 | 0.010 |
Why?
|
| Incidence | 1 | 2014 | 20320 | 0.010 |
Why?
|
| Diet | 1 | 2013 | 7392 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13468 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 2303 | 0.010 |
Why?
|
| Eating | 1 | 1996 | 1443 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1996 | 1938 | 0.010 |
Why?
|
| Obesity | 1 | 1988 | 12031 | 0.000 |
Why?
|
Concepts
(191)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_